Mucosal melanomas: A case-based review of the literature

Oncologist

Volumn 15, Issue 7, 2010, Pages 772-781

  Seetharamu, Nagashree ^a   Ott, Patrick A ^a   Pavlick, Anna C ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; DACARBAZINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; IMC 1121B; INTERFERON ALPHA2B; INTERLEUKIN 2; MELANOMA VACCINE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; STEM CELL FACTOR RECEPTOR; TAMOXIFEN; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADVANCED CANCER; ANUS CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; DRUG MEGADOSE; EYE CANCER; FEMALE GENITAL TRACT CANCER; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MELANOMA; MOUTH CANCER; ONCOGENE C KIT; OVERALL SURVIVAL; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RECTUM CANCER; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; FEMALE; GENITAL NEOPLASMS, FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUCOUS MEMBRANE; NEOPLASM STAGING; PROGNOSIS; RECTAL NEOPLASMS; SKIN NEOPLASMS;

EID: 77956117540     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0067     Document Type: Article

References (110)

1. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: A summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998; 83: 1664-1678.
2. McLaughlin CC, Wu XC, Jemal A et al. Incidence of noncutaneous melanomas in the U.S. Cancer 2005; 103: 1000-1007.
3. Lincoln RP. A case of melano-sarcoma of the nose cured by galvanocauterization. N Y Med J 1885; 42: 406-407.
4. Pandey M, Mathew A, Abraham EK et al. Primary malignant melanoma of the mucous membranes. Eur J Surg Oncol 1998; 24: 303-307.
5. Broomhall C. Malignant melanoma of the oral cavity in Ugandan Africans. Br J Surg 1967; 54: 581-584.
6. Takagi M, Ishikawa G, Mori W. Primary malignant melanoma of the oral cavity in Japan. With special reference to mucosal melanosis. Cancer 1974; 34: 358-370.
7. Wong JH, Cagle LA, Storm FK et al. Natural history of surgically treated mucosal melanoma. Am J Surg 1987; 154: 54-57.
8. Goldman JA, Lawson W, Zak FG et al. The presence of melanocytes in the human larynx. Laryngoscope 1972; 82: 824-835.
9. Hussein MR. Extracutaneous malignant melanomas. Cancer Invest 2008; 26: 516-534.
10. Szabo G. The number of melanocytes in human epidermis. BMJ 1954; 1: 1016-1017.
11. Zak FG, Lawson W. The presence of melanocytes in the nasal cavity. Ann Otol Rhinol Laryngol 1974; 83: 515-519.
12. Axéll T, Hedin CA. Epidemiologic study of excessive oral melanin pigmentation with special reference to the influence of tobacco habits. Scand J Dent Res 1982; 90: 434-442.
13. Liversedge RL. Oral malignant melanoma. Br J Oral Surg 1975; 13: 40-55.
14. Manolidis S, Donald PJ. Malignant mucosal melanoma of the head and neck: Review of the literature and report of 14 patients. Cancer 1997; 80: 1373-1386.
15. Rapini RP, Golitz LE, Greer RO Jr et al. Primary malignant melanoma of the oral cavity. A review of 177 cases. Cancer 1985; 55: 1543-1551.
16. Rapini RP. Oral melanoma: Diagnosis and treatment. Semin Cutan Med Surg 1997; 16: 320-322.
17. Chaudry AP, Hampel A, Gorlin RJ. Primary malignant melanoma of the oral cavity: A review of 105 cases. Cancer 1958; 11: 923-928.
18. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
19. Cruz F 3rd, Rubin BP, Wilson D et al. Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res 2003; 63: 5761-5766.
20. Rimoldi D, Salvi S, Lienard D et al. Lack of BRAF mutations in uveal melanoma. Cancer Res 2003; 63: 5712-5715.
21. Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-2147.
22. van Dijk M, Sprenger S, Rombout P et al. Distinct chromosomal aberrations in sinonasal mucosal melanoma as detected by comparative genomic hybridization. Genes Chromosomes Cancer 2003; 36: 151-158.
23. Curtin JA, Busam K, Pinkel D et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24: 4340-4346.
24. Rivera RS, Nagatsuka H, Gunduz M et al. C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch 2008; 452: 27-32.
25. Antonescu CR, Busam KJ, Francone TD et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 2007; 121: 257-264.
26. Lennartsson J, Jelacic T, Linnekin D et al. Normal and oncogenic forms of the receptor tyrosine kinase kit. STEM CELLS 2005; 23: 16-43.
27. Ali S, Ali S. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST). Gene 2007; 401: 38-45.
28. Nelson JD, Cameron JD. The conjunctiva: Anatomy and physiology. In: Krachmer JH, Mannis MJ, Holland EJ (eds). Cornea, Second Edition, Vol. 1. Philadelphia: Elsevier Mosby, 2005: 37-43.
29. Vajdic CM, Kricker A, GiblinMet al. Sun exposure predicts risk of ocular melanoma in Australia. Int J Cancer 2002; 101: 175-182.
30. Damato B, Coupland SE. Conjunctival melanoma and melanosis: A reappraisal of terminology, classification and staging. Clin Experiment Ophthalmol 2008; 36: 786-795.
31. Shields JA, Shields CL, Mashayekhi A et al. Primary acquired melanosis of the conjunctiva: Experience with 311 eyes. Trans Am Ophthalmol Soc 2007; 105: 61-71; discussion 71-72.
32. Furdova A, Pesko K, Strmen P et al. Conjunctival nevus and melanoma. Bratisl Lek Listy 2007; 108: 287-291.
33. Kato T, Takematsu H, Tomita Y et al. Malignant melanoma of mucous membranes. A clinicopathologic study of 13 cases in Japanese patients. Arch Dermatol 1987; 123: 216-220.
34. Batsakis JG, Regezi JA, Solomon AR et al. The pathology of head and neck tumors: Mucosal melanomas, part 13. Head Neck Surg 1982; 4: 404-418.
35. Rose DS. Nuclear pseudoinclusions in melanocytic naevi and melanomas. J Clin Pathol 1995; 48: 676-677.
36. Notani K, Shindoh M, Yamazaki Y. Amelanotic malignant melanomas of the oral mucosa. Br J Oral Maxillofac Surg 2002; 40: 195-200.
37. Hofmann U, Megahed M. [Amelanotic nodular malignant melanoma of the vulva. Case report and review of the literature]. Hautarzt 1995; 46: 850-853.
38. Ulmer A, Dietl J, Schaumburg-Lever G et al. Amelanotic malignant melanoma of the vulva. Case report and review of the literature. Arch Gynecol Obstet 1996; 259: 45-50.
39. An J, Li B, Wu L et al. Primary malignant amelanotic melanoma of the female genital tract: Report of two cases and review of literature. Melanoma Res 2009; 19: 267-270.
40. Soames JV. The morphology and quantitative distribution of dopa-positive melanocytes in the gingival epithelium of Caucasians. Oral Surg Oral Med Oral Pathol 1974; 38: 254-258.
41. Prasad ML, Jungbluth AA, Iversen K et al. Expression of melanocytic differentiation markers in malignant melanomas of the oral and sinonasal mucosa. Am J Surg Pathol 2001; 25: 782-787.
42. Bridger AG, Smee D, Baldwin MA et al. Experience with mucosal melanoma of the nose and paranasal sinuses. ANZ J Surg 2005; 75: 192-197.
43. Serrone L, Zeuli M, Sega FM et al. Dacarbazine-based chemotherapy for metastatic melanoma: Thirty-year experience overview. J Exp Clin Cancer Res 2000; 19: 21-34.
44. Middleton MR, Grob JJ, Aaronson N et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158-166.
45. Chapman PB, Einhorn LH, Meyers ML et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17: 2745-2751.
46. Bedikian AY, Millward M, Pehamberger H et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24: 4738-4745.
47. Pavlick AC, Adams S, Fink MA et al. Novel therapeutic agents under investigation for malignant melanoma. Expert Opin Investig Drugs 2003; 12: 1545-1558.
48. eetharamu N, Ott PA, Pavlick AC. Novel therapeutics for melanoma. Expert Rev Anticancer Ther 2009; 9: 839-849.
49. Torres-Cabala CA, Wang WL, Trent J et al. Correlation between KIT expression and KIT mutation in melanoma: A study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 2009; 22: 1446-1456.
50. Hodi FS, Friedlander P, Corless CL et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008; 26: 2046-2051.
51. Lutzky J, Bauer J, Bastian BC. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 2008; 21: 492-493.
52. Jiang X, Zhou J, Yuen NK et al. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res 2008; 14: 7726-7732.
53. Iversen K, Robins RE. Mucosal malignant melanomas. Am J Surg 1980; 139: 660-664.
54. Patel SG, Prasad ML, Escrig M et al. Primary mucosal malignant melanoma of the head and neck. Head Neck 2002; 24: 247-257.
55. Stern SJ, Guillamondegui OM. Mucosal melanoma of the head and neck. Head Neck 1991; 13: 22-27.
56. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
57. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-3648.
58. Hicks MJ, Flaitz CM. Oral mucosal melanoma: Epidemiology and pathobiology. Oral Oncol 2000; 36: 152-169.
59. Patrick RJ, Fenske NA, Messina JL. Primary mucosal melanoma. J Am Acad Dermatol 2007; 56: 828-834.
60. Tomicic J, Wanebo HJ. Mucosal melanomas. Surg Clin North Am 2003; 83: 237-252.
61. Johnson IJ, Warfield AT, Smallman LA et al. Primary malignant melanoma of the pharynx. J Laryngol Otol 1994; 108: 275-277.
62. Andersen LJ, Berthelsen A, Hansen HS. Malignant melanoma of the upper respiratory tract and the oral cavity. J Otolaryngol 1992; 21: 180-185.
63. Holdcraft J, Gallagher JC. Malignant melanomas of the nasal and paranasal sinus mucosa. Ann Otol Rhinol Laryngol 1969; 78: 5-20.
64. Barker BF, Carpenter WM, Daniels TE et al. Oral mucosal melanomas: The WESTOP Banff workshop proceedings. Western Society of Teachers of Oral Pathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 83: 672-679.
65. Harwood AR, Dancuart F, Fitzpatrick PJ et al. Radiotherapy in nonlentiginous melanoma of the head and neck. Cancer 1981; 48: 2599-2605.
66. Berthelsen A, Andersen AP, Jensen TS et al. Melanomas of the mucosa in the oral cavity and the upper respiratory passages. Cancer 1984; 54: 907-912.
67. Blatchford SJ, Koopmann CF Jr. Coulthard SW. Mucosal melanoma of the head and neck. Laryngoscope 1986; 96: 929-934.
68. Hoyt DJ, Jordan T, Fisher SR. Mucosal melanoma of the head and neck. Arch Otolaryngol Head Neck Surg 1989; 115: 1096-1099.
69. Lee SP, Shimizu KT, Tran LM et al. Mucosal melanoma of the head and neck: The impact of local control on survival. Laryngoscope 1994; 104: 121-126.
70. Matias C, Corde J, Soares J. Primary malignant melanoma of the nasal cavity: A clinicopathologic study of nine cases. J Surg Oncol 1988; 39: 29-32.
71. Panje WR, Moran WJ. Melanoma of the upper aerodigestive tract: A review of 21 cases. Head Neck Surg 1986; 8: 309-312.
72. Garzino-Demo P, Fasolis M, MaggioreGMet al. Oral mucosal melanoma: A series of case reports. J Craniomaxillofac Surg 2004; 32: 251-257.
73. Medina JE, Ferlito A, Brandwein MS et al. Current management of cutaneous malignant melanoma of the head and neck. Acta Otolaryngol 2002; 122: 900-906.
74. Clark RR, Shoaib T. Sentinel lymph node biopsy: A new perspective in head and neck mucosal melanoma? Melanoma Res 2007; 17: 59.
75. Owens JM, Roberts DB, Myers JN. The role of postoperative adjuvant radiation therapy in the treatment of mucosal melanomas of the head and neck region. Arch Otolaryngol Head Neck Surg 2003; 129: 864-868.
76. Mendenhall WM, Amdur RJ, HinermanRWet al. Head and neck mucosal melanoma. Am J Clin Oncol 2005; 28: 626-630.
77. Wagner M, Morris CG, Werning JW et al. Mucosal melanoma of the head and neck. Am J Clin Oncol 2008; 31: 43-48.
78. Lawson D, Kirkwood JM. Granulocyte-macrophage colony-stimulating factor: Another cytokine with adjuvant therapeutic benefit in melanoma? J Clin Oncol 2000; 18: 1603-1605.
79. Hewitt P. Sequel to a case of recurrent melanosis of both groins and back: The disease reappearing in the brain, heart, pancreas, liver and other organs. Lancet 1861: 263-264.
80. Bradgate MG, Rollason TP, McConkey CC et al. Malignant melanoma of the vulva: A clinicopathological study of 50 women. Br J Obstet Gynaecol 1990; 97: 124-133.
81. Ragnarsson-Olding BK, Nilsson BR, Kanter-Lewensohn LR et al. Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: Predictors of survival. Cancer 1999; 86: 1285-1293.
82. Weinstock MA. Malignant melanoma of the vulva and vagina in the United States: Patterns of incidence and population-based estimates of survival. Am J Obstet Gynecol 1994; 171: 1225-1230.
83. Wechter ME, Gruber SB, Haefner HK et al. Vulvar melanoma: A report of 20 cases and review of the literature. J Am Acad Dermatol 2004; 50: 554-562.
84. Ragnarsson-Olding BK, Kanter-Lewensohn LR, Lagerlöf B et al. Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: Clinical observations and histopathologic features. Cancer 1999; 86: 1273-1284.
85. DeMatos P, Tyler D, Seigler HF. Mucosal melanoma of the female genitalia: A clinicopathologic study of forty-three cases at Duke University Medical Center. Surgery 1998; 124: 38-48.
86. Raspagliesi F, Ditto A, Paladini D et al. Prognostic indicators in melanoma of the vulva. Ann Surg Oncol 2000; 7: 738-742.
87. Modifications in the staging for stage I vulvar and stage I cervical cancer Report of the FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet 1995; 50: 215-216.
88. Greene FL, Page DL, Fleming ID et al. (eds). Melanoma of the Skin. AJCC Cancer Staging Manual, Sixth Edition. New York: Springer-Verlag, 2002.
89. Chung AF, Woodruff JM, Lewis JL Jr. Malignant melanoma of the vulva: A report of 44 cases. Obstet Gynecol 1975; 45: 638-646.
90. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172: 902-908.
91. Phillips GL, Bundy BN, Okagaki T et al. Malignant melanoma of the vulva treated by radical hemivulvectomy. A prospective study of the Gynecologic Oncology Group. Cancer 1994; 73: 2626-2632.
92. Davidson T, Kissin M, Westbury G. Vulvo-vaginal melanoma-should radical surgery be abandoned? Br J Obstet Gynaecol 1987; 94: 473-476.
93. Rogo KO, Andersson R, Edbom G et al. Conservative surgery for vulvovaginal melanoma. Eur J Gynaecol Oncol 1991; 12: 113-119.
94. Trimble EL, Lewis JL Jr, Williams LL et al. Management of vulvar melanoma. Gynecol Oncol 1992; 45: 254-258.
95. Irvin WP Jr, Legallo RL, Stoler MH et al. Vulvar melanoma: A retrospective analysis and literature review. Gynecol Oncol 2001; 83: 457-465.
96. Abramova L, Parekh J, Irvin WP Jr et al. Sentinel node biopsy in vulvar and vaginal melanoma: Presentation of six cases and a literature review. Ann Surg Oncol 2002; 9: 840-846.
97. Levenback C, Burke TW, Gershenson DM et al. Intraoperative lymphatic mapping for vulvar cancer. Obstet Gynecol 1994; 84: 163-167.
98. Levenback C, Coleman RL, Burke TW et al. Intraoperative lymphatic mapping and sentinel node identification with blue dye in patients with vulvar cancer. Gynecol Oncol 2001; 83: 276-281.
99. Ramirez PT, Levenback C. Sentinel nodes in gynecologic malignancies. Curr Opin Oncol 2001; 13: 403-407.
100. Terada KY, Shimizu DM, Wong JH. Sentinel node dissection and ultrastaging in squamous cell cancer of the vulva. Gynecol Oncol 2000; 76: 40-44.
101. Wanebo HJ, Woodruff JM, Farr GH et al. Anorectal melanoma. Cancer 1981; 47: 1891-1900.
102. Roumen RM. Anorectal melanoma in The Netherlands: A report of 63 patients. Eur J Surg Oncol 1996; 22: 598-601.
103. Cagir B, Whiteford MH, Topham A et al. Changing epidemiology of anorectal melanoma. Dis Colon Rectum 1999; 42: 1203-1208.
104. Ballo MT, Gershenwald JE, Zagars GK et al. Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol 2002; 20: 4555-4558.
105. Brady MS, Kavolius JP, Quan SH. Anorectal melanoma. A 64-year experience at Memorial Sloan-Kettering Cancer Center. Dis Colon Rectum 1995; 38: 146-151.
106. Cooper PH, Mills SE, Allen MS Jr. Malignant melanoma of the anus: Report of 12 patients and analysis of 255 additional cases. Dis Colon Rectum 1982; 25: 693-703.
107. Felz MW, Winburn GB, Kallab AM et al. Anal melanoma: An aggressive malignancy masquerading as hemorrhoids. South Med J 2001; 94: 880-885.
108. Thibault C, Sagar P, Nivatvongs S et al. Anorectal melanoma-an incurable disease? Dis Colon Rectum 1997; 40: 661-668.
109. Koch SE, Lange JR. Amelanotic melanoma: The great masquerader. JAm Acad Dermatol 2000; 42: 731-744.
110. Goldman S, Glimelius B, Pahlman L. Anorectal malignant melanoma in Sweden. Report of 49 patients. Dis Colon Rectum 1990; 33: 874-877.